Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Candel Therapeutics, Inc.NASDAQ: CADL

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables grows, but more slowly than its trailing trend

Q1 FY2026 accounts payables of $1.7M rose 234.9% year over year, behind the +632.7% change in trailing-twelve-month accounts payables. Sequentially, it rose 5045.5% from the prior quarter.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +234.9% toward the trailing-twelve-month pace of +632.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.7M+5045.5% QoQ
Last fiscal yearDec 2025
$802K+533.5% YoY
LTMMar 2026
$1.99M+632.7% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+234.9%——
1 year+533.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
802K USD
Year-over-year change
+533.5%
4-year CAGR
+4.6%

Accounts Payables vs competitors

How CADL compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +632.7% is the highest of 9, against a peer median of -49.2%.
CADL Competitors
Accounts Payables for CADL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$3.74M USD-50.2%—1.0%
MGNXMacroGenics, Inc.LTM Mar 2026$2.31M USD-48.2%-70.5%1.5%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$2.14M USD+172.8%-54.3%0.9%
CADLCandel Therapeutics, Inc.LTM Mar 2026$1.99M USD+632.7%——
IMMXImmix Biopharma, Inc.LTM Mar 2026$1.2M USD-56.1%-3.2%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$796K USD-35.7%—0.4%
GNLXGenelux CorporationLTM Mar 2026$594K USD-134.0%—7425.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$448K USD+36.6%+70.0%—
IPSCCentury Therapeutics, Inc.LTM Mar 2026$424K USD-76.4%——
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY———
Peer median (excluding CADL) —-49.2%-28.7%1.0%

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Depreciation & Amortization232K778K1.28M990K845K
Deferred Income Tax11.51M0000
Stock-Based Compensation2.96M2.31M3.09M5.31M3.82M
Change in Working Capital(876K)71K(378K)346K2.19M
Accounts Receivables00000
Inventory00000
Accounts Payables669K(1.21M)45K(185K)802K
Other Working Capital(1.55M)1.28M(378K)531K1.39M
Other Non-Cash Items76K(15.78M)(301K)21.51M(6.98M)
Operating Cash Flow(22.22M)(31.42M)(34.24M)(27.02M)(38.31M)
Capital Expenditures(1.84M)(1.3M)(457K)(16K)(587K)
Acquisitions (Net)000027K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00177K00
Investing Cash Flow(1.84M)(1.3M)(280K)(16K)(560K)
Debt Repayment019.91M0(9.17M)36.21M
Common Stock Issued71.34M00101.76M19.89M
Common Stock Repurchased00(121K)00
Dividends Paid00000
Other Financing Activities465K64K01.69M0
Financing Cash Flow71.8M19.97M(121K)94.28M56.1M
Effect of Forex Changes00000
Net Change in Cash47.75M(12.74M)(34.65M)67.24M17.23M
Free Cash Flow(24.05M)(32.72M)(34.7M)(27.04M)(38.9M)

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.